Skip to main content

Table 1 Patient and treatment characteristics for different dose groups

From: Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study

Factor Level SaRT SbRT ScRT P value
N   259 163 180  
Gender Female 38 (14.7%) 23 (14.1%) 24 (13.3%) 0.92
Male 221 (85.3%) 140 (85.9%) 156 (86.7%)  
Age, median (IQR)   54 (45, 64) 55 (45, 63) 51 (44, 58.5) 0.030
Age ≥ 60 No 164 (63.3%) 105 (64.4%) 137 (76.1%) 0.012
Yes 95 (36.7%) 58 (35.6%) 43 (23.9%)  
HBV Positive 188 (72.6%) 115 (70.6%) 123 (68.3%) 0.17
Negative 33 (12.7%) 25 (15.3%) 38 (21.1%)  
Unknown 38 (14.7%) 23 (14.1%) 19 (10.6%)  
AFP status 0–8 80 (30.9%) 38 (23.3%) 35 (19.4%) < 0.001
8–200 95 (36.7%) 40 (24.5%) 41 (22.8%)  
200–400 16 (6.2%) 8 (4.9%) 11 (6.1%)  
> 400 56 (21.6%) 68 (41.7%) 86 (47.8%)  
Unknown 12 (4.6%) 9 (5.5%) 7 (3.9%)  
PT, median (IQR)   13.3 (12.7, 14.3) 13.4 (12.6, 14.2) 13.15 (12.5, 14.25) 0.58
INR, median (IQR)   1.11 (1.05, 1.2) 1.12 (1.05, 1.2) 1.1 (1.045, 1.215) 0.86
Tbil, median (IQR)   13.7 (9.6, 19.5) 14 (10, 21.5) 14.1 (9.85, 20.75) 0.58
Dbil, median (IQR)   5.3 (3.7, 8.7) 6.3 (4.1, 10.7) 6.4 (4.5, 10.45) 0.012
albumin, median (IQR)   38 (34.2, 41.7) 36.9 (33.5, 40.1) 35.95 (31.8, 39.4) < 0.001
AST, median (IQR)   32 (23, 48) 37 (25, 55) 41.5 (26, 59.5) 0.005
ALT, median (IQR)   31 (21, 43) 31 (20, 46) 32.5 (23.5, 49.5) 0.31
ALP, median (IQR)   86 (67, 120) 101 (78, 142) 111 (87.5, 151.5) < 0.001
ALBI score, median (IQR)   − 2.52 (− 2.83, − 2.10) − 2.38 (− 2.70, − 2.04) − 2.28 (− 2.62, − 1.93) < 0.001
ALBI grade 1 113 (43.6%) 59 (36.2%) 47 (26.1%) 0.002
2 137 (52.9%) 92 (56.4%) 123 (68.3%)  
3 9 (3.5%) 12 (7.4%) 10 (5.6%)  
CTP class A 212 (81.9%) 131 (80.4%) 139 (77.2%) 0.63
B 45 (17.4%) 30 (18.4%) 37 (20.6%)  
C 2 (0.8%) 2 (1.2%) 4 (2.2%)  
TD ≥ 42 Gy No 13 (5.0%) 69 (42.3%) 73 (40.6%) < 0.001
Yes 246 (95.0%) 94 (57.7%) 107 (59.4%)  
Fractions 1 6 (2.3%) 0 (0.0%) 0 (0.0%) < 0.001
2 6 (2.3%) 1 (0.6%) 0 (0.0%)  
3 230 (88.8%) 68 (41.7%) 44 (24.4%)  
4 11 (4.2%) 86 (52.8%) 85 (47.2%)  
5 6 (2.3%) 7 (4.3%) 47 (26.1%)  
6 0 (0.0%) 1 (0.6%) 4 (2.2%)  
Per dose, median (IQR)   15 (14, 15) 11.5 (11.125, 13) 10.5 (9, 10.625) < 0.001
Recurrence/residual disease No 137 (52.9%) 83 (50.9%) 72 (40.0%) 0.022
Yes 122 (47.1%) 80 (49.1%) 108 (60.0%)  
BCLC stage A 139 (53.7%) 45 (27.6%) 30 (16.7%) < 0.001
B 57 (22.0%) 42 (25.8%) 39 (21.7%)  
C 60 (23.2%) 74 (45.4%) 107 (59.4%)  
D 3 (1.2%) 2 (1.2%) 4 (2.2%)  
Tumor size, median (IQR)   3.7 (2.5, 6) 6 (4, 9.4) 8.1 (5.45, 11) < 0.001
  1. AFP, alpha fetal protein; ALBI, albumin-bilirubin score; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; INR, International Normalized Ratio; PT, prothrombin time;